Translocation domain of botulinum neurotoxin A subtype 2 potently induces entry into neuronal cells.
SNAP-25
botulinum neurotoxin
potency
subtypes
translocation domain
Journal
Microbiology and immunology
ISSN: 1348-0421
Titre abrégé: Microbiol Immunol
Pays: Australia
ID NLM: 7703966
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
19
11
2019
revised:
10
04
2020
accepted:
14
04
2020
pubmed:
18
4
2020
medline:
20
1
2021
entrez:
18
4
2020
Statut:
ppublish
Résumé
Botulinum neurotoxin (BoNT) is the causative agent of botulism in humans and animals. Only BoNT serotype A subtype 1 (BoNT/A1) is used clinically because of its high potency and long duration of action. BoNT/A1 and BoNT/A subtype 2 (BoNT/A2) have a high degree of amino acid sequence similarity in the light chain (LC) (96%), whereas their N-and C-terminal heavy chain (H
Identifiants
pubmed: 32301520
doi: 10.1111/1348-0421.12796
doi:
Substances chimiques
Recombinant Proteins
0
Botulinum Toxins, Type A
EC 3.4.24.69
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
502-511Informations de copyright
© 2020 The Societies and John Wiley & Sons Australia, Ltd.
Références
Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014;12:535-49.
Kammerer RA, Benoit RM. Botulinum neurotoxins: new questions arising from structural biology. Trends Biochem Sci. 2014;39:517-26.
Tsukamoto K, Kozai Y, Ihara H, et al. Identification of the receptor-binding sites in the carboxyl-terminal half of the heavy chain of botulinum neurotoxin types C and D. Microb Pathog. 2008;44:484-93.
Whitemarsh RC, Tepp WH, Bradshaw M, et al. Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro. Infect Immun. 2013;81:3894-902.
Torii Y, Kiyota N, Sugimoto N, et al. Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test. Toxicon. 2011;57:93-9.
Chen S, Barbieri JT. Unique substrate recognition by botulinum neurotoxins serotypes A and E. J Biol Chem. 2006;281:10906-11.
Henkel JS, Jacobson M, Tepp W, Pier C, Johnson EA, Barbieri JT. Catalytic properties of botulinum neurotoxin subtypes A3 and A4. Biochemistry. 2009;48:2522-8.
Kroken AR, Blum FC, Zuverink M, Barbieri JT. Entry of botulinum neurotoxin subtypes A1 and A2 into neurons. Infect Immun. 2017;85:e00795-16.
Fischer A, Mushrush DJ, Lacy DB, Montal M. Botulinum neurotoxin devoid of receptor binding domain translocates active protease. PLoS Pathog. 2008;4:e1000245.
Araye A, Goudet A, Barbier J, et al. The translocation domain of botulinum neurotoxin A moderates the propensity of the catalytic domain to interact with membranes at acidic pH. PLoS One. 2016;11:e0153401.
Lam KH, Guo Z, Krez N, et al. A viral-fusion-peptide-like molecular switch drives membrane insertion of botulinum neurotoxin A1. Nat Commun. 2018;9:5367.
Kondo H, Shimizu T, Kubonoya M, Izumi N, Takahashi M, Sakaguchi G. Titration of botulinum toxins for lethal toxicity by intravenous injection into mice. Jpn J Med Sci Biol. 1984;37:131-5.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265-75.
Horton RM, Cai ZL, Ho SN, Pease LR. Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. Biotechniques. 1990;8:528-35.
Krieglstein KG, DasGupta BR, Henschen AH. Covalent structure of botulinum neurotoxin type A: location of sulfhydryl groups, and disulfide bridges and identification of C-termini of light and heavy chains. J Protein Chem. 1994;13:49-57.
Sagane Y, Watanabe T, Kouguchi H, et al. Dichain structure of botulinum neurotoxin: identification of cleavage sites in types C, D, and F neurotoxin molecules. J Protein Chem. 1999;18:885-92.
Tsukamoto K, Arimitsu H, Ochi S, et al. P19 embryonal carcinoma cells exhibit high sensitivity to botulinum type C and D/C mosaic neurotoxins. Microbiol Immunol. 2012;56:664-72.
Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci. 2008;28:3689-96.
Pier CL, Chen C, Tepp WH, et al. Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett. 2011;585:199-206.
Koizumi H, Goto S, Okita S, et al. Spinal central effects of peripherally applied botulinum neurotoxin A in comparison between its subtypes A1 and A2. Front Neurol. 2014;5:98.
Moritz MS, Tepp WH, Bradshaw M, Johnson EA, Pellett S. Isolation and characterization of the novel botulinum neurotoxin A subtype 6. mSphere. 2018;3.
Kaji R. Clinical differences between A1 and A2 botulinum toxin subtypes. Toxicon. 2015;107:85-8.
Bradshaw M, Tepp WH, Whitemarsh RC, Pellett S, Johnson EA. Holotoxin activity of botulinum neurotoxin subtype A4 originating from a nontoxigenic Clostridium botulinum expression system. Appl Environ Microbiol. 2014;80:7415-22.
Pellett S, Bradshaw M, Tepp WH, et al. The light chain defines the duration of action of botulinum toxin serotype A subtypes. mBio. 2018;9.
Kozaki S, Nakaue S, Kamata Y. Immunological characterization of the neurotoxin produced by Clostridium botulinum type A associated with infant botulism in Japan. Microbiol Immunol. 1995;39:767-4.
Fernandez-Salas E, Wang J, Molina Y, Nelson JB, Jacky BP, Aoki KR. Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay. PLoS One. 2012;7(11):e49516.
Tsukamoto K, Kohda T, Mukamoto M, et al. Binding of Clostridium botulinum type C and D neurotoxins to ganglioside and phospholipid. Novel insights into the receptor for clostridial neurotoxins. J Biol Chem. 2005;280:35164-71.
Nakamura K, Kohda T, Umeda K, Yamamoto H, Mukamoto M, Kozaki S. Characterization of the D/C mosaic neurotoxin produced by Clostridium botulinum associated with bovine botulism in Japan. Vet Microbiol. 2010;140:147-54.
Benoit RM, Scharer MA, Wieser MM, Li X, Frey D, Kammerer RA. Crystal structure of the BoNT/A2 receptor-binding domain in complex with the luminal domain of its neuronal receptor SV2C. Sci Rep. 2017;7:43588.
Wang J, Meng J, Lawrence GW, et al. Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics. J Biol Chem. 2008;283:16993-7002.
Kohda T, Nakamura K, Hosomi K, Torii Y, Kozaki S, Mukamoto M. Characterization of the functional activity of botulinum neurotoxin subtype B6. Microbiol Immunol. 2017;61:482-9.
Pirazzini M, Henke T, Rossetto O, et al. Neutralisation of specific surface carboxylates speeds up translocation of botulinum neurotoxin type B enzymatic domain. FEBS Lett. 2013;587:3831-6.